-
公开(公告)号：US11613564B2
公开(公告)日：2023-03-28
申请号：US16886559
申请日：2020-05-28
Applicant: ALX Oncology Inc.
Inventor： Jaume Pons , Hong Wan , Sophia Randolph
IPC: C07K14/705 , A61P35/00 , C07K16/28 , C07K16/32 , A61K39/00
Abstract: Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric/gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions.
-
公开(公告)号：US11939385B2
公开(公告)日：2024-03-26
申请号：US16613774
申请日：2018-05-15
Applicant: ALX Oncology Inc.
Inventor： Marija Vrljic , Jaume Pons
CPC classification number: C07K16/2863 , A61P35/00 , C07K14/47 , C07K14/52 , C07K14/5428 , C07K14/5434 , C07K16/2818 , C07K16/32 , A61K2039/505 , C07K2317/31 , C07K2317/41 , C07K2317/55 , C07K2317/62 , C07K2317/76 , C07K2319/01 , C07K2319/30 , C07K2319/50
Abstract: The present application provides activatable antibodies comprising an antibody comprising an antigen-binding domain (ABD), wherein the ABD comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the N-terminus of the VH is fused to a first polypeptide shield moiety (S1), and the N-terminus of the VL is fused to a second polypeptide shield moiety (S2), wherein S1 comprises a first disease-sensing releasable moiety (DS1) and/or S2 comprises a second disease-sensing releasable moiety (DS2), wherein association of S1 with S2 blocks binding of the ABD to its target, and wherein the ABD does not specifically bind to S1, S2, or association thereof. Composition, methods of treatment using the activatable antibodies, and methods of preparation thereof are further provided.
-
公开(公告)号：US11292850B2
公开(公告)日：2022-04-05
申请号：US16359799
申请日：2019-03-20
Applicant: ALX Oncology Inc.
Inventor： Jaume Pons , Bang Janet Sim , Hong Wan , Tracy Chia-Chien Kuo
Abstract: Provided herein, inter alia, are isolated, humanized antibodies that bind an extracellular domain of a human SIRP-α polypeptide. Also provided are polynucleotides, vectors, host cells, and methods of production and use related thereto.
-
公开(公告)号：US11242404B2
公开(公告)日：2022-02-08
申请号：US17337176
申请日：2021-06-02
Applicant: ALX Oncology Inc.
Inventor： Jaume Pons , Bang Janet Sim , Hong Wan , Tracy Chia-Chien Kuo , Steven Elliot Kauder , William Don Harriman , Shelley Izquierdo
Abstract: Provided herein, inter alia, are isolated antibodies that bind an extracellular domain of a human SIRP-α v1 polypeptide (e.g., the D1 domain), an extracellular domain of a human SIRP-α v2 polypeptide, or both. In some embodiments, the antibodies also bind an extracellular domain of a monkey SIRP-α polypeptide, an extracellular domain of a mouse SIRP-α polypeptide, an extracellular domain of a human SIRP-β polypeptide, and/or an extracellular domain of a human SIRP-γ polypeptide. In some embodiments, the antibodies block or do not binding between an extracellular domain of a human SIRP-α polypeptide and an IgSF domain of a human CD47 polypeptide, while in some embodiments, the antibodies reduce the affinity of a human SIRP-α polypeptide for binding an IgSF domain of a human CD47 polypeptide. Further provided herein are methods, polynucleotides, vectors, and host cells related thereto.
-
公开(公告)号：US11208459B2
公开(公告)日：2021-12-28
申请号：US16825850
申请日：2020-03-20
Applicant: ALX Oncology Inc.
Inventor： Jaume Pons , Bang Janet Sim , Steven Elliot Kauder , Hong Wan , Tracy Chia-Chien Kuo
IPC: A61K38/17 , A61K47/68 , C07K14/47 , C07K16/28 , C07K19/00 , C07K14/705 , A61K39/395 , A61K45/06 , C07K16/00 , A61K38/00 , A61K39/00
Abstract: The present disclosure features signal-regulatory protein α (SIRP-α) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-α constructs include a high affinity SIRP-α D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-α. The SIRP-α polypeptides or constructs include a SIRP-α D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein α (SIRP-α) D1 variant and (ii) an antibody.
-
公开(公告)号：US10696730B2
公开(公告)日：2020-06-30
申请号：US16153404
申请日：2018-10-05
Applicant: ALX Oncology Inc.
Inventor： Jaume Pons , Bang Janet Sim , Steven Elliot Kauder , Hong Wan , Tracy Chia-Chien Kuo
IPC: A61K38/17 , A61K47/68 , C07K14/47 , C07K16/28 , C07K19/00 , C07K14/705 , A61K39/395 , A61K45/06 , C07K16/00 , A61K38/00 , A61K39/00
Abstract: The present disclosure features signal-regulatory protein α (SIRPα) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-α constructs include a high affinity SIRP-α D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-α. The SIRP-α polypeptides or constructs include a SIRP-α D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein α (SIRP-α) D1 variant and (ii) an antibody.
-
公开(公告)号：US20250011737A1
公开(公告)日：2025-01-09
申请号：US18441339
申请日：2024-02-14
Applicant: ALX Oncology Inc.
Inventor： Laura DEMING , Corey Goodman , Jaume Pons , Bang Janet Sim , Marija Vrljic
Abstract: The invention relates to compositions and methods of constructs comprising a SIRP-α polypeptide, including SIRP-α variants. The constructs may be engineered in a variety of ways to respond to environmental factors, such as pH, hypoxia, and/or the presence of tumor-associated enzymes or tumor-associated antigens. The constructs of the invention may be used to treat various diseases, such as cancer, preferably solid tumor or hematological cancer.
-
公开(公告)号：US12098214B2
公开(公告)日：2024-09-24
申请号：US17743350
申请日：2022-05-12
Applicant: ALX Oncology Inc.
Inventor： Hong Wan , Bang Janet Sim , Sophia Randolph , Jaume Pons , Tracy Chia-Chien Kuo
CPC classification number: C07K16/32 , A61P35/00 , A61K2039/505 , C07K2317/24 , C07K2319/02 , C07K2319/03 , C07K2319/30
Abstract: Provided are methods of treating cancer that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα D1 domain variant and an Fc domain variant in combination with at least one chemotherapy agent and/or at least one therapeutic antibody. Also provided are related kits.
-
公开(公告)号：US11939393B2
公开(公告)日：2024-03-26
申请号：US17677873
申请日：2022-02-22
Applicant: ALX Oncology Inc.
Inventor： Jaume Pons , Bang Janet Sim , Hong Wan , Tracy Chia-Chien Kuo
CPC classification number: C07K16/2896 , A61P35/00 , C07K16/2818 , C07K16/2827 , A61K45/06
Abstract: Provided herein, inter alia, are isolated, humanized antibodies that bind an extracellular domain of a human SIRP-α polypeptide. Also provided are polynucleotides, vectors, host cells, and methods of production and use related thereto.
-
公开(公告)号：US11639376B2
公开(公告)日：2023-05-02
申请号：US16736651
申请日：2020-01-07
Applicant: ALX Oncology Inc.
Inventor： Jaume Pons , Laura Deming , Corey Goodman , Bang Janet Sim , Steven Elliot Kauder , Hong Wan , Tracy Chia-Chien Kuo
IPC: A61K38/17 , A61K47/68 , C07K14/47 , C07K16/28 , C07K19/00 , C07K14/705 , A61K39/395 , A61K45/06 , C07K16/00 , A61K38/00 , A61K39/00
Abstract: The present disclosure features signal-regulatory protein α (SIRP-α) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-α constructs include a high affinity SIRP-α D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-α. The SIRP-α polypeptides or constructs include a SIRP-α D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein α (SIRP-α) D1 variant and (ii) an antibody.
